Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
about
Rituximab: mechanism of actionPhase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersMyalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristicsTumor antigen-specific monoclonal antibodies and induction of T-cell immunityBone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistanceImmunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusionMechanisms of action of therapeutic antibodies for cancerStatins impair antitumor effects of rituximab by inducing conformational changes of CD20Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphomaInduction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity UltrasoundAntibody Therapies in Cancer.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaImmunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BLExpression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004.Endogenous neurotrophins and Trk signaling in diffuse large B cell lymphoma cell lines are involved in sensitivity to rituximab-induced apoptosis.Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasMonoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Yin yang 1 is a novel regulator of pulmonary fibrosisIL-13 induces YY1 through the AKT pathway in lung fibroblasts.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies.Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsCancer immunotherapy: Progress and challenges in the clinical setting.Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.Cell death in health and diseaseUse of antibodies and immunoconjugates for the therapy of more accessible cancers.GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoproteinMolecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era.Targeting the BCL-2 family in malignancies of germinal centre origin.Understanding and circumventing resistance to anticancer monoclonal antibodies.
P2860
Q24607358-7098DC13-25B5-40B1-B660-F6C2A6F06859Q24646379-1B08432F-5DD7-4503-80C9-038B0FA48FFDQ26998412-18E1973A-10BE-407C-A312-493E2F45F9D5Q27009908-1B22FDCA-2239-46C3-87B3-D3173B66E82AQ28243054-361E669A-D8DC-4380-87F0-2ABBC2334D1AQ28296706-F2778AC0-6879-4BAA-BCD3-0D5D8E844268Q28385366-19FEEA1B-A43C-4A44-A2CB-D66AA524907CQ28472420-F4BDA5A5-CE1A-49CD-B7CF-D6FACA71D4F9Q28486745-2AA67BD9-0ACD-4D36-B792-8998B53729BEQ30366081-8BA8AE4A-A60A-4675-B334-41C455134F70Q31104000-C5BE0AC9-4B52-4C5F-A07C-52A9BAFAB15AQ33388196-3EDBAEF7-27AA-484F-9876-E9371FC6766AQ33576327-37354F14-EF06-40B6-8548-6161D17017BBQ33709463-E241A436-D279-47B2-939C-BFFC2DF97E43Q33832087-4336EA6E-8DEF-4B52-96F5-1E9E0D2AA24AQ34056575-C9CCF11D-5817-443D-A567-4465C95F182FQ34072659-DD0C122E-9C1D-4ED4-A954-2498C1057858Q34194706-4CD27625-F635-4F8E-A2E9-C82BC8076B3EQ34369841-5A051B8A-0EF3-46A4-B82D-EC5F76138A24Q34700655-9E40E514-5532-4737-A777-DADB61F9E2FDQ35107241-05CCD0DC-8CEE-49A2-A273-A99495FFE0A0Q35182151-7D2A9662-7014-4662-A02A-41F1203C868AQ35218515-2FBF2798-B65D-4EDB-B952-D118E9993681Q35562656-049DC3D6-DADF-473C-95E0-F3435DD509EAQ35919697-DA7DF3A5-DFA1-4ACB-9597-9773278D4EE1Q36184314-6D7A0B9E-FAE3-455C-BA76-3464CD02732CQ36366077-2416A518-38C6-43EA-B39E-06A0991EDB60Q36464689-B9C0E948-3E8B-476B-9B83-31B6F68B30F5Q36528137-66B46381-E5C7-49C7-BAB9-3A84721F3A36Q36754719-49C5DC87-428D-4FE0-9624-587B12054870Q36981694-51A9A0E4-97FE-40C6-A407-14CB71D697F9Q37010413-6B5D4278-DA3F-4DBD-B708-DEA135F24CDCQ37174938-361F37B7-D246-4029-AC76-33C18A6B2466Q37271831-05715CEC-52D8-4BAC-9E1C-32947A394DCFQ37273485-7B11CD2F-B0CE-45C9-AC8C-F1824011B6BEQ37288826-1B8BF39C-78E4-40C9-96AB-BFD0633AD683Q37448352-49063B43-2D5B-4815-9DDE-F4FD17BF51C6Q37470997-E0067B47-3647-45F6-9133-F0F5A9315E39Q37634558-9516D47F-725D-45FF-A70A-5F215A9CECF7Q37672125-D1399143-E44B-4DAB-87A6-E494B8CDDBD0
P2860
Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Rituximab-induced inhibition o ...... vel therapeutic interventions.
@en
type
label
Rituximab-induced inhibition o ...... vel therapeutic interventions.
@en
prefLabel
Rituximab-induced inhibition o ...... vel therapeutic interventions.
@en
P2860
P356
P1433
P1476
Rituximab-induced inhibition o ...... vel therapeutic interventions.
@en
P2093
Bonavida B
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210365
P407
P577
2007-05-01T00:00:00Z